Stability and solidification of thymol-loaded
self-microemulsifying drug delivery system

k 2024

Stability and solidification of thymol-loaded self-microemulsifying drug delivery system

KOUTNÁ, Gabriela, Jan MUSELÍK, Kateřina KUBOVÁ, Jakub VYSLOUŽIL, David VETCHÝ et. al.

Basic information

Original name

Stability and solidification of thymol-loaded self-microemulsifying drug delivery system

Authors

KOUTNÁ, Gabriela (203 Czech Republic, belonging to the institution), Jan MUSELÍK (203 Czech Republic, guarantor, belonging to the institution), Kateřina KUBOVÁ (203 Czech Republic, belonging to the institution), Jakub VYSLOUŽIL (203 Czech Republic, belonging to the institution), David VETCHÝ (203 Czech Republic, belonging to the institution), Jan KOTOUČEK (203 Czech Republic) and Josef MAŠEK (203 Czech Republic)

Edition

14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 2024

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Pharmacy

Keywords in English

self-microemulsifying system; thymol; stability; solidification

Abstract

V originále

Self-emulsifying drug delivery systems (SEDDS) have gained recognition as a crucial approach to enhancing the bioavailability of poorly water-soluble drugs. Thymol boasts a plethora of biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. Thymol is a GRAS candidate for preventing and treating inflammatory bowel diseases. Given their limited bioavailability, thymol presents a promising candidate for inclusion in self-emulsifying systems. Nevertheless, liquid SEDDS pose challenges, including the potential irritation caused by a high surfactant content on the gastrointestinal mucosa, reduced formulation stability, and complexities in handling. Solid SEDDS, conversely, are solidified self-emulsifying formulations achieved by converting liquid SEDDS into self-emulsifying powders or particles. Neusilin® US2 was chosen as the solid carrier for thymol SMEDDS formulation. The optimized T-SMEDDS formulations underwent long-term stability tests, and six months stability was demonstrated. The optimal ratio of T-SMEDDS formulation with the solid carrier Neusilin® US2 was 2:1. In vitro dissolution characteristics was determined using biorelevant media FaSSIF. The release of more than 85% of thymol from the T-SMEEDS formulation within 15 minutes indicates a reasonable presumption for enhanced thymol bioavailability in the biosystem.

Links

GA22-03187S, research and development project

Name: Racionální design částicových polysacharidových systémů pro přívod léčiv s širokým spekterem biologické aktivity k terapii sliznic (Acronym: 22-03187S)

Investor: Czech Science Foundation

Citovat

KOUTNÁ, Gabriela, Jan MUSELÍK, Kateřina KUBOVÁ, Jakub VYSLOUŽIL, David VETCHÝ, Jan KOTOUČEK and Josef MAŠEK. Stability and solidification of thymol-loaded self-microemulsifying drug delivery system. In 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. 2024.

@proceedings{2393304,
   author = {Koutná, Gabriela and Muselík, Jan and Kubová, Kateřina and Vysloužil, Jakub and Vetchý, David and Kotouček, Jan and Mašek, Josef},
   booktitle = {14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology},
   keywords = {self-microemulsifying system; thymol; stability; solidification},
   language = {eng},
   title = {Stability and solidification of thymol-loaded self-microemulsifying drug delivery system},
   year = {2024}
}

TY  - CONF
ID  - 2393304
AU  - Koutná, Gabriela - Muselík, Jan - Kubová, Kateřina - Vysloužil, Jakub - Vetchý, David - Kotouček, Jan - Mašek, Josef
PY  - 2024
TI  - Stability and solidification of thymol-loaded self-microemulsifying drug delivery system
KW  - self-microemulsifying system
KW  - thymol
KW  - stability
KW  - solidification
N2  - Self-emulsifying drug delivery systems (SEDDS) have gained recognition as a crucial approach to enhancing the bioavailability of poorly water-soluble drugs. Thymol boasts a plethora of biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. Thymol is a GRAS candidate for preventing and treating inflammatory bowel diseases. Given their limited bioavailability, thymol presents a promising candidate for inclusion in self-emulsifying systems. Nevertheless, liquid SEDDS pose challenges, including the potential irritation caused by a high surfactant content on the gastrointestinal mucosa, reduced formulation stability, and complexities in handling. Solid SEDDS, conversely, are solidified self-emulsifying formulations achieved by converting liquid SEDDS into self-emulsifying powders or particles. Neusilin® US2 was chosen as the solid carrier for thymol SMEDDS formulation. The optimized T-SMEDDS formulations underwent long-term stability tests, and six months stability was demonstrated. The optimal ratio of T-SMEDDS formulation with the solid carrier Neusilin® US2 was 2:1. In vitro dissolution characteristics was determined using biorelevant media FaSSIF. The release of more than 85% of thymol from the T-SMEEDS formulation within 15 minutes indicates a reasonable presumption for enhanced thymol bioavailability in the biosystem.
ER  -

KOUTNÁ, Gabriela, Jan MUSELÍK, Kateřina KUBOVÁ, Jakub VYSLOUŽIL, David VETCHÝ, Jan KOTOUČEK and Josef MAŠEK. Stability and solidification of thymol-loaded self-microemulsifying drug delivery system. In \textit{14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology}. 2024.

Detailed Information on Publication Record